利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

13 条记录 (耗时 0.023 秒)

    Selective glucagon-like-peptide-2 (GLP-2) analogues
    1.
    发明授权
    Selective glucagon-like-peptide-2 (GLP-2) analogues 有权

    公开(公告)号：US10092648B2

    公开(公告)日：2018-10-09

    申请号：US14172680

    申请日：2014-02-04

    申请人： Zealand Pharma A/S

    发明人： Bjarne Due Larsen ,  Yvette Miata Petersen

    IPC分类号： A61K38/26 ,  A61K45/06 ,  C07K14/605

    摘要： GLP-2 analogs are disclosed which comprise one of more substitutions as compared to h[Gly2]GLP-2 and which may have the property of an increased small intestine/colon and stomach/colon selectivity. More particularly, preferred GLP-2 analogs disclosed herein comprise substitutions at one or more of positions 11, 16, 20, 24 and/or 28 of the wild-type GLP-2 sequence, optionally in combination with further substitutions at position 2 and one or more of positions 3, 5, 7, and 10, and/or a deletion of one or more of amino acids 31 to 33 and/or the addition of a N-terminal or C-terminal stabilizing peptide sequence. The analogs are particularly useful for the prophylaxis or treatment of stomach and bowel-related disorders and for ameliorating side effects of chemotherapy.

    Method of treating stomach or bowel-related disorders by administering glucagon-like-peptide-2 (GLP-2) analogues
    2.
    发明授权
    Method of treating stomach or bowel-related disorders by administering glucagon-like-peptide-2 (GLP-2) analogues 有权
    通过施用胰高血糖素样肽-2（GLP-2）类似物来治疗胃或肠相关疾病的方法

    公开(公告)号：US09580487B2

    公开(公告)日：2017-02-28

    申请号：US14847938

    申请日：2015-09-08

    申请人： Zealand Pharma A/S

    发明人： Bjarne Due Larsen ,  Yvette Miata Petersen

    IPC分类号： A61K38/26 ,  C07K14/605 ,  A61K35/54 ,  A61K35/74 ,  C12N7/00 ,  C07K14/47 ,  A61K48/00

    CPC分类号： C07K14/605 ,  A61K9/0019 ,  A61K9/19 ,  A61K35/54 ,  A61K35/74 ,  A61K38/00 ,  A61K38/26 ,  A61K47/26 ,  A61K48/00 ,  C12N7/00 ,  C12N2710/10043 ,  C12N2710/20043 ,  C12N2710/22043 ,  C12N2760/20243

    摘要： GLP-2 analogs are disclosed which comprise one of more substitutions as compared to [hGly2]GLP-2 and which improved biological activity in vivo and/or improved chemical stability, e.g., as assessed in in vitro stability assays. More particularly, preferred GLP-2 analogs disclosed herein comprise substitutions at one or more of positions 8, 16, 24 and/or 28 of the wild-type GLP-2 sequence, optionally in combination with further substitutions at position 2 (as mentioned in the introduction) and one or more of positions 3, 5, 7, 10 and 11, and/or a deletion of one or more of amino acids 31 to 33 and/or the addition of a N-terminal or C-terminal stabilizing peptide sequence. The analogs are particularly useful for the prophylaxis or treatment of stomach and bowel-related disorders and for ameliorating side effects of chemotherapy. Also disclosed are methods and kits for selecting a patient from populations suited for treatment with GLP-2 analogs.

    摘要翻译： 公开了GLP-2类似物，其包含与[hGly2] GLP-2相比更多的取代之一，并且其在体内和/或改善的化学稳定性方面得到改善的生物学活性，例如在体外稳定性测定中评估。 更具体地，本文公开的优选的GLP-2类似物在野生型GLP-2序列的8,16,24和/或28位的一个或多个位置上任选地与第2位上的进一步取代组合（如 引入）和位置3,5,7,10和11中的一个或多个，和/或缺失一个或多个氨基酸31至33和/或添加N-末端或C-末端稳定肽 序列。 类似物对预防或治疗胃和肠道相关疾病以及改善化学疗法的副作用特别有用。 还公开了用于从适合于用GLP-2类似物治疗的群体中选择患者的方法和试剂盒。